CASP1 and COVID-19: As shown in a recent study, activation of the inflammasome in SARS-CoV-2-infected lung-resistant macrophages is the major driver of COVID-19, and the subsequent inhibition of the inflammasome with small molecules targeting NLRP3 or caspase-1 reverses chronic lung pathology [127].